Medicine and Dentistry
Community-Acquired Pneumonia
100%
Streptococcus Pneumonia
25%
Diseases
24%
Pathogen
23%
Cohort Effect
22%
Pneumococcal Pneumonia
21%
Comorbidity
21%
Antibiotic Therapy
15%
Macrolide
15%
Respiratory Tract Infection
13%
COVID-19
13%
Antibiotics
13%
Infection
12%
Infectious Disease
12%
Clinician
12%
Respiratory Disease
11%
Surveillance System
11%
Influenza Vaccine
10%
Influenza B
9%
Odds Ratio
9%
Intensive Care Unit
9%
Observational Study
9%
Septic Shock
9%
Sepsis
8%
Systematic Review
8%
Influenza Vaccination
8%
Randomized Controlled Trial
7%
Immune Response
7%
Nucleic Acid Analysis
7%
Prevalence
7%
Clinical Trial
7%
Placebo
7%
Thorax Radiography
7%
Lung
6%
Respiratory Failure
6%
Tumor Necrosis Factor
6%
Monotherapy
6%
Adverse Event
6%
Computer Assisted Tomography
6%
Diagnosis
6%
Pleura Effusion
6%
Hypertensive Factor
6%
Health Care Associated Pneumonia
6%
Bronchiectasis
5%
Pneumococcus
5%
Effusion
5%
Biological Marker
5%
Hospital Mortality
5%
Polymerase Chain Reaction
5%
Influenza A (H1N1)
5%
Pharmacology, Toxicology and Pharmaceutical Science
Community Acquired Pneumonia
48%
Diseases
30%
Macrolide
19%
Infection
16%
Antibiotics
14%
Infectious Agent
14%
Respiratory Tract Infection
10%
Comorbidity
9%
Streptococcus Pneumonia
8%
Sepsis
8%
Clinical Trial
7%
Antibiotic Therapy
7%
Adverse Event
7%
Respiratory Tract Disease
6%
Monotherapy
6%
Chronic Obstructive Lung Disease
6%
Cystic Fibrosis
6%
Procalcitonin
5%
Coronavirinae
5%
Pseudomonas aeruginosa
5%
Dexamethasone
5%
Molgramostim
5%
Pharmacokinetics
5%
Live Attenuated Influenza Vaccine
5%
Beta Lactam
5%
Immunology and Microbiology
Streptococcus Pneumonia
13%
Infectious Agent
11%
Immune Response
11%
Influenza
11%
Lymphotoxin Alpha
9%
Pneumococcus
9%
Tumor Necrosis Factor
9%
Haplotype
8%
Interleukin 10
7%
Inflammation Response
6%
Mononuclear Cell
6%
Nontuberculous mycobacteria
6%
Promoter Region
6%
Pseudomonas aeruginosa
5%
Macrophage
5%
Molgramostim
5%
Gram-Negative Bacteria
5%
Microbiome
5%
Comorbidity
5%